The FDA has given the OK to Excision BioTherapeutics to begin human trials on a treatment and possible cure for HIV. The treatment is based on CRISPR technology and requires just one infusion.
CRISPR is a technology to edit genes. It finds a specific bit of DNA inside a cell and alters that bit of DNA.
So far, three people have been cured of HIV when they received bone marrow transplants as a treatment for cancer. The donors had genes that were resistant to HIV. This was not a practical cure for HIV, however, because the risk of a bone marrow transplant is much greater than the risk of taking HIV medication such as Truvada.
The treatment Excision developed finds HIV in the body and cuts it in three places to deactivate the virus cells. Cutting it in just one place allows the remaining HIV cell to mutate around the cut.
The infusion cut the amount of HIV in mice but two-thirds remained somewhat infected, according to FreeThink.com that reported the story. The question is how much of the HIV needs to be deactivated for the treatment to be considered a cure and for someone with HIV to live a normal lifespan without taking daily medication.
— David Taffet